ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: "Lipocine, Inc." (LPCN) Report Updated: Sep 14, 2014 | Print This Page

Get more stock ratings by Louis Navellier

"Lipocine, Inc." (LPCN)

Rating: Strong Sell Volatility: Aggressive
Total Grade: F Industry: Pharmaceuticals
Competitors: SHPG, TXMD, MRK, BDSI

Stock Analysis

Rating: Monthly View

A
B
C
D
F
September October November December January February March April May June July August

Rating: Weekly View

This Week: F down downgrade
Last Week: D same no change
Two Weeks Ago: D up upgrade
service keys

"Lipocine, Inc."© quotemedia

Company Profile

Lipocine Inc., a specialty pharmaceutical company, is engaged in the development of pharmaceutical products in the areas of menís and womenís health. The company offers a portfolio of proprietary product candidates that are used to produce pharmacokinetic characteristics; facilitate lower dosing requirements and bypass first-pass metabolism; reduce side effects; and eliminate gastrointestinal interactions that limit bioavailability. Its product candidates for menís health include LPCN 1021, an oral product candidate, which is in Phase III clinical trials; and LPCN 1111, an oral product candidate that is in Phase I/II clinical trials for the treatment of testosterone replacement therapy. The companyís product candidates for womenís health comprise LPCN 1107, which is in Phase I/II clinical trials for the prevention of preterm birth. Lipocine Inc. was founded in 1997 and is headquartered in Salt Lake City, Utah.

Recent News: "Lipocine, Inc."